NCT06005740View on ClinicalTrials.gov

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Advanced Solid TumorHepatocellular Carcinoma
Interventions
DRUG

TORL-4-500

antibody drug conjugate

Trial Locations (10)

22031

RECRUITING

Virginia Cancer Specialists, Lexington

32224

RECRUITING

Mayo Clinic Jacksonville, Jacksonville

32827

RECRUITING

Florida Cancer Specialists Lake Nona Drug Development Unit, Orlando

55905

RECRUITING

Mayo Clinic Rochester, Rochester

85054

RECRUITING

Mayo Clinic Phoenix, Phoenix

90095

RECRUITING

UCLA - JCCC Clinical Research Unit, Los Angeles

90505

RECRUITING

Torrance Memorial Physician Network, Torrance

92835

RECRUITING

Providence Medical Foundation, Fullerton

M5G 2M9

RECRUITING

University Health Network, Princess Margaret Cancer Centre, Toronto

H4A 3J1

RECRUITING

McGill University Health Centre, Montreal

All Listed Sponsors
collaborator

Translational Research in Oncology

OTHER

lead

TORL Biotherapeutics, LLC

INDUSTRY